

Global Health Clinics Ltd.
400-837 West Hastings Street
Vancouver, BC V6C 3N6
Tel: 1.855.537.6272

NOT FOR DISSEMINATION IN THE UNITED STATES

NEWS RELEASE

GLOBAL HEALTH CLINICS CLOSED ACQUISITION OF WONDER SCIENTIFIC

Vancouver, BC, January 20, 2021 – Global Health Clinics Ltd. (CSE: MJRX / FRANKFURT: L002) (“**Global Health**” or the “**Company**”) is pleased to announce that it has closed the acquisition of Wonder Scientific, as previously announced by the Company on December 11, 2020.

About Wonder Scientific

Wonder Scientific is a development-stage plant medicine company focused on the mental health and natural health & wellness marketplace, with a focus on research related to psilocybin. Wonder Scientific’s mission is to unlock the healing properties of new plant medicines sourced from unique locations around the world; transforming them into regulated and safe pharmaceutical products for global commercialization and sales. Wonder Scientific’s researchers and product development experts are seeking to create custom, naturally derived, active pharmaceutical ingredients (APIs) to supply the growing global clinical and commercial demand for psychedelics.

The Wonder Scientific team has focused on its key corporate objectives of sourcing and securing access to federally licensed work & bench space required for formulation and manufacturing work in the B2B sales channels of the industry. The team at Wonder Scientific includes:

Tegan Adams: Ms. Adams’ background is in Sustainable Commercial Agriculture and international trade policy, with a focus on efficient farming, providing her with global contacts in mycology and botany. Ms. Adams is experienced in product development and has acted as past internal director of a Health Canada accredited testing lab. Ms. Adams is also a co-founder and past CEO of a private equity holdings group in Toronto with access to EU-GMP, GMP and commercial agriculture facilities with over 1.5M ft² production space.

Dr. Andrew Riseman: Dr. Riseman is a professor of Applied Biology & Plant Breeding at the University of British Columbia in Vancouver, British Columbia. A tenured professor and past member of the UBC Senate, Dr. Riseman specializes in nutrient management and biomass optimization production methods applicable to the fungi & wild plant discovery routes that Wonder is working within. Dr. Riseman is a co-founder and major shareholder of a company providing optimal nutrient management product for hydroponics production & regulated cannabis and other greenhouse grown products.

Istok Nahtigal: Mr. Nahtigal is a specialized biochemical processing engineer and supercritical fluid extraction expert. His past work in product development with BioNiche, LaVaas and MedReleaf leads

him to be specialized in IP strategy, natural bioprocessing techniques and other innovation in extraction and active compound isolation. A specialist in product innovation, Mr. Nahtigal is an active member of the association of chemical professionals in Ontario.

Angela Caruk: Ms. Caruk is a Registered Clinical Counsellor with an MA in Counselling Psychology. Her work combines Jungian techniques with a body-centered approach called Focusing-Oriented Therapy. With 10 years experience as a therapist with couples and individuals and 14+ years providing short and long-term counselling, Ms. Caruk specializes in a variety of presenting issues including depression, anxiety, PTSD and complex trauma. Having had experience with integrating psychedelics into therapy through section 56 exemptions from the *Controlled Drugs and Substances Act*, Ms. Caruk provides input into the psychedelics and mental health aspects of Wonder Scientific.

In October 2020, a Controlled Substances Dealer's Licence application was prepared and submitted by Wonder Scientific to the Controlled Drugs Section of Health Canada's Office of Controlled Substances of Health. There can be no assurance that such license will be granted by Health Canada.

In November 2020, the Company, through Dr. Riseman, procured initial spores for research and development at the University of British Columbia. The research proposal is focused on researching optimal production for psilocybin mushrooms, mycelium productions and the creation of a genetics library. Wonder Scientific intends to procure and create fresh tissues of fungi by basing tissue production on aseptic tissue culture technologies in laboratories. The contemplated technologies are intended to allow Wonder Scientific to generate 'pure cultures' (e.g. single genotypes) to be grown under sterile conditions for research and commercial production. Wonder Scientific is amassing a library of *psilocybe* genetics for analysis to determine optimal genetics for commercial production, including biomass production, rate of growth and production of psilocybin.

To date, the Company is focussed on developing new products to supply clinical trials, creating products for regulated markets and resellers, as well as creating custom active pharmaceutical formulations and contract manufacturer quality agreements. The existing research project, lab space and growing genetics library at UBC, as well as Wonder Scientific's in-house expertise, established agreements with channel partners for research and production and its Controlled Substances Dealer's Licence application will establish Wonder Scientific as a supplier of clean-start *psilocybe* genetics to the psychedelics research and novel drug development sector.

Transaction Details

Pursuant to a Share Purchase Agreement dated December 10, 2020, among the Company, 2756407 Ontario Ltd. ("**Wonder Scientific**") and the shareholders of Wonder Scientific, the Company has acquired 100% ownership of Wonder Scientific, through the issuance to the Wonder Scientific shareholders of an aggregate of 26,000,000 common shares, at a deemed price of \$0.1725 per share ("**Consideration Shares**").

The Company is at arms-length from Wonder Scientific and its shareholders. The Consideration Shares are subject to a voluntary pooling arrangement and (a) 3,979,132 of the Consideration Shares will be subject to a 12-month pooling arrangement, whereby 50% of such shares will be released six months from the closing of the Transaction (the "**Closing**") and the remaining 50% of such shares will be released six months after that; and (b) 22,020,868 of the Consideration Shares will be subject to a four-month and one day pooling arrangement, whereby 33% of such shares will be released on Closing,

33% will be released two months after Closing and the remaining 34% will be released four months and one day after Closing. In connection with the completion of the Transaction, the Company has also issued 2,100,000 common shares to arm's length parties who assisted with the Transaction.

“We are excited to acquire Wonder Scientific. The transaction provides access to their team of experienced pharmacologists and product experts in the natural health space,” said Jatinder Dhaliwal, Chief Executive Officer of the Company.

ON BEHALF OF THE BOARD OF DIRECTORS

GLOBAL HEALTH CLINICS LTD.

Jatinder Dhaliwal
Chief Executive Officer

For further information, readers are encouraged to contact Jatinder Dhaliwal, Chief Executive Officer, at 1.855.537.6272

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Information

Except for the statements of historical fact, this news release contains “forward-looking information” within the meaning of the applicable Canadian securities legislation that is based on expectations, estimates and projections as at the date of this news release. “Forward-looking information” in this news release includes information about the Transaction, including the intentions, plans and future actions of the Company and Wonder Scientific. The forward-looking information in this news release reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available to the Company. Although the Company believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance and accordingly undue reliance should not be put on such information due to the inherent uncertainty therein. The Company provides forward looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.